Neuroblastoma and MYCN

Neuroblastoma, the most common extracranial solid tumor of childhood, is thought to originate from undifferentiated neural crest cells. Amplification of the MYC family member, MYCN, is found in ∼25% of cases and correlates with high-risk disease and poor prognosis. Currently, amplification of MYCN remains the best-characterized genetic marker of risk in neuroblastoma. This article reviews roles for MYCN in neuroblastoma and highlights recent identification of other driver mutations. Strategies to target MYCN at the level of protein stability and transcription are also reviewed.

• AC
  American Cancer Society

  Award: PF-13-295-01-TBG
• AL
  Alex's Lemonade Stand Foundation for Childhood Cancer

  Awards: CA159859, CA148699
• PB
  Pediatric Brain Tumor Foundation
• NI
  National Institutes of Health

  Awards: CA163155, CA148699, CA128583